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David N. Juurlink, MD, PhDa,b,c,i , Canadian Drug Safety and Effectiveness Research Network (CDSERN) Ontario, CanadaBackground Among patients taking warfarin, lower socioeconomic status is associated with poorer control of
anticoagulation. However, the extent to which socioeconomic status influences the risk of hemorrhage is unknown. We
examined the extent to which socioeconomic status influences the risk of hemorrhage in older individuals newly commencing
warfarin therapy for atrial fibrillation.
Methods We conducted a population-based cohort study of individuals 66 years or older with atrial fibrillation who
commenced warfarin therapy between April 1, 1997, and November 30th 2011, in Ontario, Canada. We used
neighborhood-level income quintiles as a measure of socioeconomic status. The primary outcome was an emergency
department visit or hospitalization for hemorrhage, and the secondary outcome was fatal hemorrhage.
Results We studied 166,742 older patients with atrial fibrillation who commenced warfarin therapy. Of these, 16,371
(9.8%) were hospitalized for hemorrhage during a median follow-up of 369 (interquartile range 102-865) days. After
multivariable adjustment using Cox proportional hazards regression, we found that those in the lowest-income quintile faced an
increased risk of hospitalization for hemorrhage relative to those in the highest quintile (adjusted hazard ratio 1.18, 95% CI
1.12-1.23). Similarly, the risk of fatal hemorrhage (n = 1,802) was increased in the lowest-income relative to the highest-
income quintile (adjusted hazard ratio 1.28, 95% CI 1.11-1.48).
Conclusions Among older individuals receiving warfarin therapy for atrial fibrillation, lower socioeconomic status is a
risk factor for hemorrhage and hemorrhage-related mortality. This factor should be carefully considered when initiating and
monitoring warfarin therapy. (Am Heart J 2015;170:133-140.e3.)Socioeconomic differences in health outcomes are
ubiquitous, even in countries with universal health
care.1–5 Such disparities may reflect differences in disease
severity, lifestyle, or the prevalence of risk factors, but
may also stem from differential access to physicians'
services,6 diagnostic imaging and screening examina-o, Ontario, Canada
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,tions,7,8 and appropriate medications,9 among other
factors. In the context of stroke, several studies suggest
that lower socioeconomic status is a risk factor for stroke,
stroke-specific mortality, and poorer short-term and
long-term survival after stroke.4
Atrial fibrillation is a major modifiable risk factor for
ischemic stroke,10 and treating its consequences consumes
more than 1% of all global health care expenditures each
year.11 With the prevalence of atrial fibrillation expected to
more than double by 2050,12 anticoagulants will represent
an increasingly important public health intervention in the
coming years. In patients with atrial fibrillation, warfarin
reduces the risk of stroke by roughly two-thirds and all-cause
mortality by more than 25%.13 However, warfarin has a
narrow therapeutic window, requires frequent monitoring,
and is associated with an increased risk of hemorrhage and
hemorrhage-related mortality.14
Several factors influence the risk of hemorrhage during
warfarin therapy, including age, drug adherence, adequa-
cy of monitoring, bleeding history, comorbidity, and drug
interactions.15 Less is known about the extent to which
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hemorrhage. Some data suggest that social deprivation is
associated with an increased risk of hemorrhage in the
general population,16 as well as in those receiving
anticoagulants,15 whereas lower socioeconomic status is
associated with reduced time in the therapeutic range.17
We examined the relationship between socioeconomic
status and risk of hemorrhage in a large population of
individuals commencing warfarin therapy for atrial fibril-
lation. We hypothesized that patients of lower socioeco-
nomic status may be at greater risk for hemorrhage and
hemorrhage-associatedmortality relative to those of higher
socioeconomic status.
Methods
Setting and design
We conducted a population-based cohort study of
individuals 66 years or older who commenced warfarin
therapy between April 1, 1997, and November 30, 2011,
in Ontario, Canada. These individuals had universal access
to hospital care, physician services, and prescription drug
coverage. This project was approved by the Research
Ethics Board of Sunnybrook Health Sciences Centre,
Toronto, Ontario, Canada. This project was supported by
research funds from Canadian Drug Safety and Effective-
ness Research Network and by the Institute for Clinical
Evaluative Sciences, which is funded by a grant from the
Ontario Ministry of Health and Long-Term Care.
Data sources
We identified outpatient prescription records using the
Ontario Drug Benefit Database, which contains compre-
hensive records of prescription drugs dispensed to all
Ontarians 65 years or older. We obtained hospitalization
data from the Canadian Institute for Health Information
Discharge Abstract Database, which contains detailed
information regarding all hospital admissions, and data on
emergency department visits from the Canadian Institute
for Health Information National Ambulatory Care Report-
ing System. We established the presence of diabetes
mellitus, congestive heart failure, and hypertension using
validated disease-specific databases.18–20 Basic demo-
graphic information was acquired from the Ontario
Health Insurance Plan (OHIP) Registered Persons Data-
base, a registry of all Ontario residents eligible for public
health insurance. Physicians' services were identified
using the OHIP Claims History Database. These databases
were linked in an anonymous fashion using unique
encrypted Ontario health insurance numbers and are
routinely used to study drug safety.21
Socioeconomic status definition
We linked the Statistics Canada Census with individual
postal codes at the time of cohort entry, using the
Statistics Canada Postal Code Conversion File (PCCF+Version 5 F) to obtain median neighborhood income
quintile at the level of the dissemination area. The
dissemination area is the smallest geographical unit used
for reporting census data and provides a better estimate
of individual-level socioeconomic status than larger
reporting areas.22 This approach is routinely used to
study the consequences of socioeconomic disparities on
health outcomes in Ontario.23–26
Study subjects
We identified all individuals 66 years or older with a
diagnosis of atrial fibrillation using previously validated
International Classification of Diseases, Ninth Revision
(ICD-9) and International Classification of Diseases
and Related Health Problems, 10th Revision (ICD-10)
diagnosis codes.27 Within the cohort of subjects with
atrial fibrillation, we identified patients newly treated
with warfarin, excluding those with any warfarin
prescription in the preceding year. Consequently, the
date of the initial warfarin prescription constituted the
date of cohort entry.
For each patient, we defined a period of continuous
warfarin therapy beginning with the first prescription
after their 66th birthday and ending with hospitalization
for hemorrhage, discontinuation of treatment, death, or
the end of the study period, whichever occurred first. We
did not study patients during their first year of eligibility
for prescription drug coverage (age 65 years) to avoid
incomplete medication records. Patients were deemed to
have discontinued treatment if more than 180 days lapsed
between successive prescriptions; in such cases, obser-
vation was extended for 100 days (the maximum funded
prescription duration) from the date of the last prescrip-
tion to identify events that may have precipitated
cessation of therapy.
Outcomes
The primary outcome was an emergency department visit
or hospital admission for hemorrhage (onlineAppendixA).28
Because we hypothesized that patients of lower socioeco-
nomic status might be at a greater risk for mortality from
hemorrhage, we conducted a secondary analysis to investi-
gate the relationship between socioeconomic status and risk
of fatal hemorrhage.
Statistical analysis
We constructed a cumulative incidence function to
estimate the incidence of hemorrhage in each income
quintile during follow-up. These analyses treated all-cause
mortality and drug discontinuation as competing events,
either of which would preclude hemorrhage. To facilitate
comparison with clinical trials, we calculated overall and
income quintile–specific hemorrhage rates from the total
number of hemorrhage events and sum of follow-up time.
We conducted time-to-event analyses using Cox pro-
portional hazard regression to examine the association
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of hemorrhage. To test the proportional hazards assumption,
we visually inspected the estimated log (−log) survival
curves and tested the statistical significanceof the interaction
between follow-up time and the variable denoting socio-
economic status. To optimize model fit for the primary
outcome, we included an interaction term between
socioeconomic status and a quadratic function of follow-up
time for the fourth income quintile because the proportional
hazards assumption was violated. We therefore allowed the
effect of the fourth income quintile (relative to that of the
highest-incomequintile) to vary over time. For the secondary
outcome (fatal hemorrhage), we included a linear interac-
tion between socioeconomic status and follow-up time.
To test the robustness of our main analysis, we
examined the relationship between socioeconomic status
and hemorrhage subtype (gastrointestinal, intracranial
hemorrhage or other; online Appendix A). In this
analysis, events were not mutually exclusive. All subjects
presenting with more than 1 hemorrhage subtype were
included in each of the respective analyses.
We adjusted all models for baseline characteristics (age,
sex, long-term care residence, and rural place of residence),
calendar year of warfarin initiation, comorbidity (defined
using both an adaptation of theCharlsonComorbidity Index
and the number of distinct drugs dispensed in the year
preceding cohort entry29), documented alcohol use disor-
der, evidence of liver disease in the preceding 3 years,
kidney disease in the preceding 3 years, anemia in the
preceding 3 years, malignancy in the preceding 3 years,
hemorrhage in the preceding 3 years, and CHADS2
1 score.
Individual comorbidities were determined using ICD-9,
ICD-10, and OHIP diagnostic codes, as outlined in online
Appendix B. Potentially interacting drugs (acetylsalicylic
acid, other antiplatelet agents, other nonsteroidal anti-in-
flammatory drugs, proton-pump inhibitors, acetaminophen
and acetaminophen-containing products, and selective
serotonin reuptake inhibitors) were treated as time-varying
covariates by determining utilization in successive 90-day
intervals. All analyses used a 2-sided type I error rate of .05 as
the threshold for statistical significance andwereperformed at
the Institute for Clinical Evaluative Sciences (www.ices.on.ca)
using SAS version 9.3 (SAS Institute, Cary, NC).
Results
During the 15-year study period, we identified 166,742
older patients newly treated with warfarin for atrial
fibrillation. The median age at cohort entry was 78 years,
and approximately half were men. Subjects of lower1 The CHADS2 score is used to estimate stroke risk in patients
with atrial fibrillation. It is defined by +1 point for a history of
congestive heart failure, +1 for a history of hypertension, +1 for age
N 75 years, +1 for a history of diabetes mellitus, and +2 for a history
of stroke or transient ischemic attack.socioeconomic status displayed greater comorbidity and
exposure to drugs that might heighten the risk of
hemorrhage. The characteristics of individuals in each
income quintile are shown in Table I.
We identified 16,371 subjects (9.8%) with an emergency
department visit or hospitalization for hemorrhage over a
median follow-up of 369 days (interquartile range 102-865).
Within this group, 1,802 (11.0%) died in hospital. The overall
rate of hemorrhage was 4.8% per person-year (Table II). We
identified amonotonically increasing gradient in the absolute
rates of hemorrhage events during follow-up, with a 5-year
cumulative incidence of 9.6%, 10.3%, 10.6%, 11.2%, and
11.5% for income quintiles 5 (highest income) through 1
(lowest income), respectively (Figure).
In the primary analysis, we found that patients in the
lowest-income quintile were at an increased risk of
hemorrhage relative to those in the highest-income quintile
(adjusted hazard ratio 1.18, 95% CIs 1.12-1.23) (Table III).
This increased risk was similarly observed in income
quintiles 2 through 4 compared with income quintile 5.
The hazard ratio comparing the fourth and fifth quintileswas
not uniform, but rather declined over time. In the secondary
analysis, we identified a similar association between
socioeconomic status and risk of fatal hemorrhage, with
patients in the lowest-income quintile 28%more likely to die
of warfarin-associated hemorrhage than those in the high-
est-income quintile (adjusted hazard ratio 1.28, 95% CI 1.11
to 1.48) (Table III).
In an analysis by subtype of hemorrhage, we found that
subjects in the lowest-income quintile were at an increased
risk for gastrointestinal (adjusted hazard ratio 1.18, 95% CIs
1.10 to 1.27) and other hemorrhage subtypes (adjusted
hazard ratio 1.20, 95% CIs 1.12 to 1.29) relative to those in
the highest-incomequintile (Table IV),with lesser degrees of
risk among patients in quintiles 2, 3, and 4. Interestingly,
however, we found no association between socioeconomic
status and risk of intracranial hemorrhage (Table IV).
To estimate the intensity of anticoagulant monitoring,
we examined the annual rate of international normalized
ratio (INR) testing in our cohort. We found similar rates in
each income quintile, with a mean number of INR tests
during the first year of follow-up of 20.0, 20.3, 20.5, 20.5,
and 20.6 in income quintiles 1 through 5, respectively.Discussion
In this population-based cohort study of older patients
with atrial fibrillation commencing warfarin therapy, we
found that lower socioeconomic status was associated
with an increased risk of hemorrhage and hemorrha-
ge-related mortality relative to higher socioeconomic
status. Our findings add clinical context to the previously
observed association between socioeconomic status and
anticoagulant control17 and highlight the relationship
between socioeconomic status and adverse outcomes
among patients prescribed warfarin for atrial fibrillation.
Table I. Characteristics of individuals by income quintile
Income quintile
1 (Low; n = 33,065) 2 (n = 35,734) 3 (n = 32,950) 4 (n = 31,620) 5 (High; n = 33,373)
Demographics
Age (y), median (IQR) 78 (73-83) 78 (73-83) 78 (72-83) 77 (72-83) 78 (73-83)
Male, n (%) 14,880 (45.0) 17,297 (48.4) 16,374 (49.7) 16,098 (50.9) 17,867 (53.5)
Urban, n (%) 27,647 (83.6) 30,192 (84.5) 27,981 (84.9) 27,094 (85.7) 29,029 (87.0)
Long term care, n (%) 2043 (6.8) 1799 (5.0) 1705 (5.2) 1477 (4.7) 1336 (4.0)
Prescribing physician, n (%)
Family medicine 15,396 (46.6) 16,099 (45.1) 14,905 (45.2) 14,349 (45.4) 14,906 (44.7)
Emergency 54 (0.2) 68 (0.2) 51 (0.2) 61 (0.2) 85 (0.3)
Cardiology 3950 (11.9) 4569 (12.8) 4149 (12.6) 3957 (12.5) 4084 (12.2)
Neurology 77 (0.2) 83 (0.2) 92 (0.3) 72 (0.2) 93 (0.3)
Internal medicine 1957 (5.9) 2130 (6.0) 1981 (6.0) 1908 (6.0) 1894 (5.7)
Other 2207 (6.7) 2404 (6.7) 2221 (6.7) 2125 (6.7) 2120 (6.4)
Unknown 9424 (28.5) 10,381 (29.1) 9551 (29.0) 9148 (28.9) 10,191 (30.5)
Deyo-Charlson Comorbidity Index⁎, n (%)
No hospitalization 8729 (26.4) 10,136 (28.4) 9493 (28.8) 9464 (29.9) 10,621 (31.8)
0 6199 (18.7) 6859 (19.2) 6567 (19.9) 6471 (20.5) 7087 (21.2)
1 6949 (21.1) 7235 (20.2) 6707 (20.4) 6365 (20.1) 6600 (19.8)
2+ 11,188 (33.8) 11,504 (32.2) 10,183 (30.9) 9320 (29.5) 9065 (27.2)
Comorbidities⁎, n (%)
Alcohol use 1181 (3.6) 1055 (3.0) 1018 (3.1) 914 (2.9) 912 (2.7)
Liver disease 246 (0.7) 209 (0.6) 204 (0.6) 186 (0.6) 173 (0.5)
Renal disease 3099 (9.4) 3327 (9.3) 2872 (8.7) 2654 (8.4) 2586 (7.7)
Malignancy 2265 (6.9) 2501 (7.0) 2368 (7.2) 2267 (7.2) 2385 (7.1)
Anemia 6386 (19.3) 6841 (19.1) 6050 (18.4) 5726 (18.1) 5854 (17.5)
Prior hemorrhage 1475 (4.5) 1577 (4.4) 1408 (4.3) 1200 (3.8) 1356 (4.1)
CHADS2 components, n (%)
Heart failure 12,501 (37.8) 12,745 (35.7) 11,451 (34.8) 10,363 (32.8) 10,396 (31.2)
Hypertension 26,161 (79.1) 28,138 (78.7) 25,651 (77.8) 24,356 (77.0) 25,087 (75.2)
Age N 75 y 21,565 (65.2) 22,968 (64.3) 20,754 (63.0) 19,764 (62.5) 21,070 (63.1)
Diabetes 9669 (29.2) 10,150 (28.4) 8868 (27.0) 8205 (25.9) 7667 (23.0)
Previous stroke 2991 (9.0) 3064 (8.6) 2765 (8.4) 2722 (8.6) 2690 (8.1)
CHADS2 score, n (%)
0 1604 (4.9) 1936 (5.4) 2004 (6.1) 2086 (6.6) 2535 (7.6)
1 6544 (19.8) 7497 (21.0) 7278 (22.1) 7273 (23.0) 8188 (24.5)
2 11,553 (34.9) 12,603 (35.3) 11,514 (34.9) 11,077 (35.0) 11,507 (34.5)
3 8731 (26.4) 8922 (25.0) 7990 (24.2) 7283 (23.0) 7366 (22.1)
4 3415 (10.3) 3555 (9.9) 3079 (9.3) 2875 (9.1) 2790 (8.4)
5 933 (2.8) 886 (2.5) 848 (2.6) 800 (2.5) 782 (2.3)
6 285 (0.9) 335 (0.9) 237 (0.7) 226 (0.7) 205 (0.6)
Medications, median (IQR)
Drugs in past year 9 (5-13) 9 (5-13) 8 (5-12) 8 (5-12) 8 (5-11)
Antiplatelet agents†, n (%)
ASA 6297 (19.0) 5921 (16.6) 5186 (15.7) 4445 (14.1) 4303 (12.9)
ASA and clopidogrel 140 (0.4) 136 (0.4) 110 (0.3) 131 (0.4) 95 (0.3)
ASA and dipyridamole 283 (0.9) 315 (0.9) 288 (0.9) 278 (0.9) 277 (0.8)
Clopidogrel 1484 (4.5) 1472 (4.1) 1416 (4.3) 1454 (4.6) 1351 (4.0)
Ticlopidine 244 (0.7) 240 (0.7) 241 (0.7) 183 (0.6) 229 (0.7)
Non-ASA NSAID†, n (%) 5615 (17.0) 5845 (16.4) 5352 (16.2) 4936 (15.6) 5082 (15.2)
Other interacting drugs†, n (%)
Proton-pump inhibitors 5897 (17.8) 6056 (16.9) 5319 (16.1) 5307 (16.8) 5163 (15.5)
Acetaminophen 7365 (22.3) 6958 (19.5) 6038 (18.3) 5478 (17.3) 5326 (16.0)
SSRIs 3320 (10.0) 3291 (9.2) 2952 (9.0) 2824 (8.9) 2658 (8.0)
IQR, Interquartile range; ASA, Acetylsalicylic acid; NSAID, nonsteroidal anti-inflammatory drug; SSRIs, selective serotonin reuptake inhibitors.
⁎ In the past 3 years.
† In the past 120 days.
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rin prescribing, and anticoagulation monitoring practices
may help reduce socioeconomic status–related health
disparities and the burden of warfarin-induced harm.We found that nearly 10% of older patients had an
emergency department visit or were hospitalized for
hemorrhage at some point during warfarin therapy, with
an overall rate of 4.8% per person-year. Our estimates
Table II. Crude rates of hemorrhage during continuous warfarin
therapy
Income quintile Hemorrhage rate, % per person-year
1 (Lowest) 5.3
2 5.0
3 4.8
4 4.6
5 (Highest) 4.3
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(RCTs; 0.6% to 4.2% per person-year) and observational
data (2.5%, 99% CIs 2.0%-3.1% per person-year),14 a
discrepancy with several potential explanations. Impor-
tantly, we limited our population to patients newly
treated with warfarin, when the risk of hemorrhage is
greatest,30 and the median age of our subjects is greater
than that of patients commonly included in RCTs of
warfarin therapy.14 Older patients typically have more
risk factors for hemorrhage relative to younger patients.
Finally, we followed up our cohort for up to 5 years,
whereas the duration of RCTs and observational studies is
often considerably shorter.14
Our findings were not fully explained by variations in the
prevalence ofmeasured risk factors for hemorrhage (Table I).
Socioeconomic status persisted as a risk factor for hemor-
rhage and hemorrhage-related mortality, even after adjust-
ment for demographic factors, comorbid illness, and
exposure to potential interacting medications. Although all
subjects received universal drug coverage at age 65 years, it is
plausible that those of lower socioeconomic status experi-
enced poorer management of other chronic health condi-
tions in the years preceding their eligibility for drug coverage.
As a result, these subjects may present with more advanced
disease and poorer health whenwarfarin therapy is initiated.
Our findings add to a growing body of literature
suggesting that socioeconomic status impacts individual
health, even within a universal health care system.1–5 This
may be partly explained by differences in exposure to risk
factors for cardiovascular and other disease, differences in
disease severity, inequitable access to health services, and
other determinants of health such as social and physical
environments. In the context of stroke care, although
initiation of antithrombotic therapy after strokemay not be
influenced by socioeconomic status,31 access to warfarin
therapy for stroke prophylaxis has been shown to vary
among subjects of differing social deprivation.32 Interest-
ingly, we observed a greater proportion of subjects with
CHADS2 score b 1 in the higher-income quintiles,
suggesting a lower threshold for stroke prophylaxis in
atrial fibrillation patients of higher socioeconomic status.
Up to 80% of older patients have inadequate knowledge
of warfarin therapy,33 and lower socioeconomic status
impacts health literacy, understanding of warfarin ther-
apy, and access to educational and information re-sources.33,34 Our findings accord with those of a recent
study from the United Kingdom, suggesting that social
deprivation is associated with elevated risk of hemor-
rhage in anticoagulant recipients.15 However, in contrast
to their findings, we found that socioeconomic status was
not associated with intracranial hemorrhage. This may be
due to differences in cohort selection, exposure and
outcome definitions, or differences between the Ontario
and UK health care systems. As compared with a younger
cohort, older patients typically exhibit more risk factors
for falls and intracranial hemorrhage.35 Given the median
age of our cohort, it is possible that falls and resultant
traumatic hemorrhage might mask an association be-
tween socioeconomic status and intracranial hemor-
rhage. Moreover, given the small number of intracranial
hemorrhage events in our study, it is possible that we had
insufficient statistical power to detect a difference in rates
of intracranial hemorrhage among income groups.
The results of our study are particularly relevant given
the emergence of novel anticoagulant agents such as
dabigatran, apixaban, and rivaroxaban as alternatives to
warfarin therapy. Although these agents are gaining
popularity, concerns remain regarding real-world effec-
tiveness, anticoagulation reversal in the setting of
hemorrhage, and drug interactions. This is particularly
true in older people, many of whom are preferentially
treated with warfarin. Additional study will be needed to
determine whether a socioeconomic gradient in the risk
of hemorrhage and fatal hemorrhage is also present in
patients receiving these medications.
Some limitations of our study warrant emphasis. We used
neighborhood-level income as a measure of socioeconomic
status rather than individual-level data. Although individual--
level estimatesmore strongly correlatewithhealth outcomes
than do area-level measures,36 both positively predict health
outcomes37,38 and area-level measures offer advantages,
such as the ability to capture aspects of neighborhoods that
can effect health outcomes.38 We used income as our
measure of socioeconomic status, rather than accrued
wealth, occupation, education, social class, or a composite
measure, which are not available in our databases. Although
socioeconomic status measures tend to show colinearity,
their magnitude of effect on outcomes can vary.36 Although
the generalizability of our findings to younger subjects is
unknown, atrial fibrillation is diagnosed at a mean age of 71
years,12 and the mean age in our population was 78 years.
Although we used validated diagnostic codes to define
our hemorrhage outcomes and comorbidities,18–20,27,28
some degree of outcome misclassification is possible.
Moreover, we were unable to capture hemorrhage events
that did not result in an emergency department visit or
hospitalization. Notwithstanding the fact that we adjust-
ed for many covariates, residual confounding is a
possibility. Because of the nature of our administrative
data, we were unable to account for some individual-level
factors that might impact our study findings. These might
Figure
Cumulative incidence of hemorrhage over time, by income quintile. Figure displays the cumulative incidence of hemorrhage among patients
commencing warfarin therapy for atrial fibrillation, stratified by neighborhood-level income quintile. The 5-year estimates were 11.5%, 11.2%,
10.6%, 10.3%, and 9.6% for income quintiles 1 (lowest) through 5 (highest), respectively.
Table III. Neighborhood-level income quintile and risk of
hemorrhage or fatal hemorrhage
Income quintile
Unadjusted hazard ratio
(95% CI)
Adjusted hazard ratio⁎
(95% CIs)
Hemorrhage
1 (Lowest) 1.23 (1.17-1.29) 1.18 (1.12-1.23)
2 1.17 (1.12-1.23) 1.13 (1.08-1.19)
3 1.11 (1.05-1.17) 1.08 (1.03-1.14)
4 (t0) 1.16 (1.07-1.25) 1.14 (1.05-1.23)
4 (t1 year) 1.09 (1.03-1.16) 1.08 (1.02-1.14)
4 (t2 year) 1.03 (0.95-1.11) 1.02 (0.95-1.10)
4 (t3 year) 0.99 (0.92-1.07) 0.97 (0.90-1.05)
4 (t4 year) 0.95 (0.86-1.05) 0.93 (0.84-1.02)
4 (t5 year) 0.91 (0.75-1.10) 0.89 (0.73-1.07)
5 (Highest) 1.00 (referent) 1.00 (referent)
Fatal hemorrhage
1 (Lowest) 1.37 (1.19-1.59) 1.28 (1.10-1.48)
2 1.23 (1.06-1.42) 1.17 (1.01-1.36)
3 1.04 (0.89-1.21) 1.01 (0.86-1.18)
4 (t0) 1.30 (1.06-1.59) 1.29 (1.06-1.58)
4 (t1 year) 1.18 (1.01-1.38) 1.18 (1.00-1.38)
4 (t2 year) 1.07 (0.91-1.26) 1.07 (0.91-1.25)
4 (t3 year) 0.98 (0.80-1.20) 0.97 (0.79-1.19)
4 (t4 year) 0.90 (0.68-1.16) 0.88 (0.67-1.15)
4 (t5 year) 0.81 (0.57-1.14) 0.80 (0.56-1.12)
5 (Highest) 1.00 (referent) 1.00 (referent)
⁎Adjusted for: age, sex, long-term care residence and rural place of residence,
calendar year of warfarin initiation, Charlson comorbidity index, number of distinct
drugs dispensed in the year preceding cohort entry, documented alcohol use disorder,
evidence of liver disease in the preceding 3 years, kidney disease in the preceding 3
years, anemia in the preceding 3 years, malignancy in the preceding 3 years,
hemorrhage in the preceding 3 years, and CHADS2 score. Potentially interacting
drugs including acetylsalicylic acid, other antiplatelet agents, other nonsteroidal
anti-inflammatory drugs, proton-pump inhibitors, acetaminophen, acetaminophen
containing products, and selective serotonin reuptake inhibitors were treated as
time-varying covariates by determining utilization in successive 90-day intervals.
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disease control, the degree of warfarin and other
medication adherence, or use of other medications,
such as acetylsalicylic acid and natural health products
obtained without a prescription. Moreover, we were
unable to control for ethnicity or other genetic factors,
both of which have been shown to be important
determinants of anticoagulant dosing and risk of hemor-
rhage.39,40 Finally, we did not have access to antic-
oagulation test values or data regarding follow-up at
anticoagulation clinics. Although we attempted to
account for intensity of anticoagulant monitoring by
examining the annual rate of INR testing, these data may
not necessarily reflect INR stability. Such data may
provide greater interpretability regarding the impact of
socioeconomic status on anticoagulation control.
Conclusion
In summary, among older patients who commenced
warfarin therapy for atrial fibrillation, lower socioeco-
nomic status is a risk factor for hemorrhage and
hemorrhage-related mortality. Integrating this evidence
into patient counseling, warfarin prescribing, and antic-
oagulation monitoring practices may help reduce socio-
economic status–related health disparities and reduce the
burden of warfarin-mediated harm.Acknowledgements
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time-varying covariates by determining utilization in successive 90-day intervals.
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Other hemorrhage
N020 Recurrent and persistent hematuria, minor glomerular
abnormality
N021 Recurrent and persistent hematuria, focal and segmental
glomerular lesions
N022 Recurrent and persistent hematuria, diffuse membranous
glomerulonephritis
N023 Recurrent and persistent hematuria, diffuse mesangial
proliferative glomerulonephritis
N024 Recurrent and persistent hematuria, diffuse endocapillary
proliferative glomerulonephritis
N025 Recurrent and persistent hematuria, diffuse mesangiocapillary
glomerulonephritis
N026 Recurrent and persistent hematuria, dense deposit disease
N027 Recurrent and persistent hematuria, diffuse crescentic
glomerulonephritis
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ICD-10 codesGastrointestinal hemorrhage
K920 Hematemesis
K921 Melena
I850 Esophageal varices with bleeding
I9820 Esophageal varices in diseases classified elsewhere with
bleeding
I983 Esophageal varices with bleeding in disease classified
elsewhere
K2210 Ulcer of esophagus, acute with hemorrhage
K2212 Ulcer of esophagus, acute with both hemorrhage and
perforation
K2214 Ulcer of esophagus, chronic or unspecified with hemorrhage
K2216 Ulcer of esophagus, chronic or unspecified with both
hemorrhage and perforation
K250 Gastric ulcer, acute with hemorrhage
K252 Gastric ulcer, acute with both hemorrhage and perforation
K254 Gastric ulcer, chronic or unspecified with hemorrhage
K256 Gastric ulcer, chronic or unspecified with both hemorrhage
and perforation
K260 Duodenal ulcer, acute with hemorrhage
K262 Duodenal ulcer, acute with both hemorrhage and perforation
K264 Duodenal ulcer, chronic or unspecified with hemorrhage
K266 Duodenal ulcer, chronic or unspecified with both hemorrhage
and perforation
K270 Peptic ulcer, acute with hemorrhage
K272 Peptic ulcer, acute with both hemorrhage and perforation
K274 Peptic ulcer, chronic or unspecified with hemorrhage
K276 Peptic ulcer, chronic or unspecified with both hemorrhage and
perforation
K280 Gastrojejunal ulcer, acute with hemorrhage
K282 Gastrojejunal ulcer, acute with both hemorrhage and
perforation
K284 Gastrojejunal ulcer, chronic or unspecified with hemorrhage
K286 Gastrojejunal ulcer, chronic or unspecified with both
hemorrhage and perforation
K290 Acute hemorrhagic gastritis
K6380 Angiodysplasia of small intestine, except duodenum with
bleeding
K3180 Angiodysplasia of stomach and duodenum with bleeding
K5520 Angiodysplasia of colon with bleeding
K625 Hemorrhage of anus and rectum
K922 Gastrointestinal hemorrhage, unspecified
Intracerebral hemorrhage
I60 Subarachnoid hemorrhage
I61 Intracerebral hemorrhage
I620 Subdural hemorrhage (acute)(nontraumatic)
I621 Nontraumatic extradural hemorrhage
I629 Intracranial hemorrhage (nontraumatic), unspecified
(continued on next page)
N028 Recurrent and persistent hematuria, other
N029 Recurrent and persistent hematuria, unspecified
K661 Hemoperitoneum
N938 Other specified abnormal uterine and vaginal bleeding
N939 Abnormal uterine and vaginal bleeding, unspecified
N950 Postmenopausal bleeding
R041 Hemorrhage from throat
R042 Hemoptysis
R048 Hemorrhage from other sites in respiratory passages
R049 Hemorrhage from respiratory passages, unspecified
R310 Gross hematuria
R311 Microscopic hematuria
R318 Other and unspecified hematuria
R58 Hemorrhage, not elsewhere classified
D683 Hemorrhagic disorder due to circulating anticoagulants
H356 Retinal hemorrhage
H431 Vitreous hemorrhage
H450 Vitreous hemorrhage in diseases classified elsewhere
M250 Hemarthrosis
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July 2015ICD-9 codesGastrointestinal hemorrhage
5310 Acute gastric u
5312 Acute gastric u
5314 Chronic or uns
5316 Chronic or uns
5320 Acute duoden
5322 Acute duoden
5324 Chronic or uns
5326 Chronic or uns
5330 Acute peptic u
5332 Acute peptic u
5334 Chronic or uns
5336 Chronic or uns
5340 Acute gastroje
5342 Acute gastroje
5344 Chronic or uns
5346 Chronic or uns
5780 Hematemesis
5781 Blood in stool
5789 Hemorrhage o
5693 Rectal anal he
5781 Blood in stool
5789 Gastrointestina
Intracerebral hemorrhage
430 Subarachnoid
431 Intracerebral h
4320 Nontraumatic
4321 Subdural hem
4329 Intracranial he
Other hemorrhage
2878 Other specifie
2879 Unspecified H
5967 Bladder wall h
7848 Hemorrhage f
5997 Hematuria
6271 Postmenopaus
4590 Hemorrhage,
7191 Hemarthrosis
7863 Hemoptysislcer with hemorrhage
lcer with hemorrhage and perforation
pecified gastric ulcer with hemorrhage
pecified gastric ulcer with hemorrhage and perforation
al ulcer with hemorrhage
al ulcer with hemorrhage and perforation
pecified duodenal ulcer with hemorrhage
pecified duodenal ulcer with hemorrhage and perforation
lcer of unspecified site with hemorrhage
lcer of unspecified site with hemorrhage and perforation
pecified peptic ulcer of unspecified site with hemorrhage
pecified peptic ulcer of unspecified site with hemorrhage and perforation
junal ulcer with hemorrhage, without mention of obstruction
junal ulcer with hemorrhage and perforation
pecified gastrojejunal ulcer with hemorrhage
pecified gastrojejunal ulcer with hemorrhage and perforatiom
f gastrointestinal tract, unspecified
morrhage
l hemorrhage, unspecified
hemorrhage
emorrhage
extradural hemorrhage
orrhage
morrhage NOS
d hemorrhagic condition
emorrhagic condition
emorrhage
rom throat
al bleeding
unspecified
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Alcohol use V113, 291, 303.0, 303.9, 305.0, 357.5,
425.5, 535.3, 571.0, 571.1, 571.3, 790.3,
980.0
F10, G31.2, G62.1, G72.1, I42.6, K29.2,
K70.1, K70.4, K70.9, K86.0, R78.0, T51.0,
X65, Y15, Y91, Z50.1,Z71.4, Z86.40
291, 303
Liver disease 5712, 5715, 5716, 5718, 5719, 5714,
7044, 7054
K702, K703, K740, K742, K743, K744,
K745, K746, K73, B18
571
Renal
disease
403, 4031, 4039, 4040, 4049, 585, 586,
587, 5881, 5888, 5881, 5888, 5889,25040
E102, E112, E132, E142, I12, I13, N08,
N18, N19
403, 585
Malignancy 140, 141, 142, 143, 144, 145, 146, 147,
148, 149, 150, 151, 152, 153, 154, 155,
156, 157, 158, 159, 160, 161, 162, 163,
164, 165, 166, 167, 168, 169, 170, 171,
172, 173, 174, 175, 176, 177, 178, 179,
180, 181, 182, 183, 184, 185, 186, 187,
188, 189, 190, 191, 192, 193, 194, 195,
196, 197, 198, 199, 200, 201, 202, 203,
204, 205, 206, 207, 208
C0, C1, C20, C21, C22, C23, C24, C25,
C26, C30, C31, C32, C33, C340-349, C37,
C38, C39, C40, C41, C43, C45, C46, C47,
C48, C49, C50, C51, C52, C53, C54, C55,
C56, C57, C58, C6, C70, C71, C72, C73,
C74, C75, C76, C77, C78, C79,C80, C81,
C82, C83, C84, C85, C88, C90, C91, C92,
C93, C94, C95,C96, C97, C384, C450
140, 141, 142, 143, 144, 145, 146, 147,
148, 149, 150, 151, 152, 153, 154, 155,
156, 157, 158, 159, 160, 161, 162, 163,
164, 165, 166, 167, 168, 169, 170, 171,
172, 173, 174, 175, 176, 177, 178, 179,
180, 181, 182, 183, 184, 185, 186, 187,
188, 189, 190, 191, 192, 193, 194, 195,
196, 197, 198, 199, 200, 201, 202, 203,
204, 205, 206, 207, 208
Anemia 2800, 2801, 2808, 2809, 2810, 2811,
2812, 2813, 2814, 2818, 2819, 2820,
2821, 2822, 2823, 2824, 2825, 28260,
28261, 28262, 28263, 28269, 2827, 2828,
2829, 2830, 2831, 2832, 2839, 2840,
2848, 2849, 2850, 2851, 2858, 2859
D500, D501, D508, D509, D510, D511,
D512, D513, D518, D519, D521, D528,
D529, D530, D531, D532, D538, D539,
D550, D551, D552, D553, D558, D559,
D560, D561, D562, D563, D564, D568,
D569, D570, D571, D572, D573, D578,
D580, D581, D582, D588, D589, D590,
D591, D592, D593, D594, D595, D596,
D598, D599, D600, D601, D608, D609,
D610, D611, D612, D613, D618, D619,
D62, D630, D638, D640, D641, D642,
D643, D644, D648, D649
280, 281, 282, 283, 284, 285
Hemorrhage 430, 431, 4320, 4321, 4329, 5310, 5312,
5314, 5316, 5320, 5322, 5324, 5326,
5330, 5332, 5334, 5336, 5340, 5342,
5344, 5346, 5780, 5781, 5789, 5693,
5781, 5789, 2878, 2879, 5967, 7848,
5997, 6271, 4590, 7191, 7863
I60, I61, I620, I621, I629, K920, K921,
I850, I9820, I983, K2210, K2212, K2214,
K2216, K250, K252, K254, K256, K260,
K262, K264, K266, K270, K272, K274,
K276, K280, K282, K284, K286, K290,
K6380, K3180, K5520, K625, K922, N020,
N021, N022, N023, N024, N025, N026,
N027, N028, N029, K661, N938, N939,
N950, R041, R042, R048, R049, R310,
R311, R318, R58, D683, H356, H431,
H450, M250
Heart failure 428 I500, I501 and I509
Hypertension 401, 402, 403, 404, 405 I10, I11, I12, I13, I15
Diabetes 250 Q040, K029, K030, K045, K046 (OHIP
feecodes)
Stroke 434, 436 I630, I631, I632, I633, I634, I635, I638,
I639, I64
